No connection

Search Results

TRDA

NEUTRAL
$13.56 Live
Entrada Therapeutics, Inc. · NASDAQ
Target $21.4 (+57.8%)
$4.93 52W Range $14.49
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 21, 2026
Market cap
$519.14M
P/E
N/A
ROE
-39.1%
Profit margin
N/A
Debt/Equity
0.17
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
75%
TRDA presents a classic high-risk, high-reward biotechnology profile, anchored by a stable Piotroski F-Score of 6/9. While the company exhibits extreme operating losses and a severe YoY revenue decline of 96.5%, its financial health is bolstered by an exceptional current ratio of 12.53, indicating a massive cash runway. There is a stark divergence between the 'Strong Buy' analyst consensus with a $21.40 target and the bearish insider sentiment characterized by consistent C-suite selling. The valuation is speculative, trading at a high Price/Sales multiple of 20.42 with no current earnings.

Key Strengths

Exceptional liquidity with a current ratio of 12.53
Very low leverage with a Debt/Equity ratio of 0.17
Stable Piotroski F-Score (6/9) indicating decent operational health for a biotech
Strong analyst conviction with a 'Strong Buy' rating and significant upside target
Strong 1-year price performance (+70.6%)

Key Risks

Extreme operating margin deficit (-3103%) indicating high cash burn
Severe revenue collapse (-96.5% YoY), likely due to the end of a milestone payment
Bearish insider activity with multiple sales by the CFO and President
Lack of profitability with negative ROE (-39.13%) and ROA (-21.58%)
High valuation relative to sales (P/S of 20.42)
AI Fair Value Estimate
Based on comprehensive analysis
$21.4
+57.8% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
41
Moderate
Value
20
Future
60
Past
40
Health
85
Dividend
0
AI Verdict
Speculative Hold
Key drivers: Cash runway, Analyst targets, Insider selling, Revenue volatility
Confidence
80%
Value
20/100

Ref P/E N/A, P/S 20.42

Positives
  • Price/Book is relatively modest at 1.59
Watchpoints
  • P/S ratio of 20.42 is very high
  • No Graham Number available due to negative earnings
Future
60/100

Ref Growth rates and Analyst Targets

Positives
  • Strong analyst target price of $21.40
  • Recent 6-month price surge (+117%)
Watchpoints
  • Negative YoY revenue growth
  • Forward P/E remains negative
Past
40/100

Ref Historical price and EPS trends

Positives
  • Significant 1-year recovery
Watchpoints
  • 5-year change is negative (-43.4%)
  • Highly volatile quarterly earnings surprises
Health
85/100

Ref Piotroski F-Score and Liquidity Ratios

Positives
  • Piotroski F-Score of 6/9 is stable
  • Current Ratio of 12.53 is elite
  • Debt/Equity is very low
Watchpoints
  • Altman Z-Score not provided
Dividend
0/100

Ref Yield N/A

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$13.56
Analyst Target
$21.4
Upside/Downside
+57.8%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for TRDA and closest competitors.

Updated 2026-04-20
TRD
Entrada Therapeutics, Inc.
Primary
5Y
-43.4%
3Y
-5.2%
1Y
+70.6%
6M
+117.0%
1M
+19.9%
1W
-2.4%
NPC
NeuroPace, Inc.
Peer
5Y
-38.5%
3Y
+219.8%
1Y
+43.9%
6M
+41.9%
1M
+8.2%
1W
+5.8%
OFI
Orthofix Medical Inc.
Peer
5Y
-70.9%
3Y
-30.2%
1Y
-4.0%
6M
-14.4%
1M
+8.4%
1W
+5.5%
STR
Sutro Biopharma, Inc.
Peer
5Y
-83.1%
3Y
-30.0%
1Y
+506.7%
6M
+212.4%
1M
+44.8%
1W
+22.0%
EMB
Embecta Corp.
Peer
5Y
-78.3%
3Y
-65.2%
1Y
-18.7%
6M
-34.0%
1M
-3.8%
1W
+1.0%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-3.94
PEG Ratio
N/A
P/B Ratio
1.59
P/S Ratio
20.42
EV/Revenue
9.57
EV/EBITDA
-1.6
Market Cap
$519.14M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -3103.0%
Gross Margin N/A
ROE -39.13%
ROA -21.58%

Growth

Revenue and earnings growth rates

Revenue Growth -96.5%
Earnings Growth N/A
Q/Q Revenue Growth -96.53%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.17
Low debt
Current Ratio
12.53
Strong
Quick Ratio
12.2
Excellent
Cash/Share
$8.21

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Op. Margin
-3249.3%
Net Margin
-3014.9%
Total Assets
$0.4B
Liabilities
$0.1B
Equity
$0.3B
Debt/Equity
0.23x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
99%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07
$N/A
2026-02-26
$-0.94
+18.7% surprise
2025-11-06
$-1.06
-9.8% surprise
2025-08-06
$-1.04
-20.5% surprise

Healthcare Sector Comparison

Comparing TRDA against 498 companies in the Healthcare sector (28 bullish, 153 neutral, 317 bearish)
Return on Equity (ROE)
-39.13%
This Stock
vs
-95.47%
Sector Avg
-59.0% (Below Avg)
Debt to Equity
0.17
This Stock
vs
2.89
Sector Avg
-94.2% (Less Debt)
Revenue Growth
-96.5%
This Stock
vs
137.48%
Sector Avg
-170.2% (Slower)
Current Ratio
12.53
This Stock
vs
4.66
Sector Avg
+168.7% (Stronger)

Similar Companies

Peer comparison within the same industry

TRDA Entrada...
NEUTRAL
Mkt Cap
$519M
P/E
-
ROE
-39.1%
Price
$13.56
NPCE NeuroPace, Inc.
NEUTRAL
Mkt Cap
$517M
P/E
-
ROE
-158.7%
Price
$15.35
 Compare with TRDA
OFIX Orthofix Medical Inc.
BEARISH
Mkt Cap
$517M
P/E
-
ROE
-19.3%
Price
$12.87
 Compare with TRDA
STRO Sutro Biopharma, Inc.
BEARISH
Mkt Cap
$523M
P/E
-
ROE
-%
Price
$31.55
 Compare with TRDA
EMBC Embecta Corp.
NEUTRAL
Mkt Cap
$526M
P/E
3.7
ROE
-%
Price
$8.88
 Compare with TRDA

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

WENTWORTH KORY JAMES
Chief Financial Officer
Sell
2026-04-01
2,500 shares · $32,375
WENTWORTH KORY JAMES
Chief Financial Officer
Sell
2026-03-10
16,477 shares · $214,379
DOWDEN NATHAN J
President
Sell
2026-03-10
15,010 shares · $195,771
WENTWORTH KORY JAMES
Chief Financial Officer
Sell
2026-03-04
7,988 shares · $97,892
DOSHI DIPAL
Chief Executive Officer
Stock Award
2026-02-27
139,400 shares
WENTWORTH KORY JAMES
Chief Financial Officer
Stock Award
2026-02-27
44,600 shares
DOWDEN NATHAN J
President
Stock Award
2026-02-27
55,800 shares
SETHURAMAN NATARAJAN
Officer
Stock Award
2026-02-27
55,800 shares
WENTWORTH KORY JAMES
Chief Financial Officer
Sell
2025-11-21
8,910 shares · $88,932
BAKER BROS ADVISORS L.P.
Beneficial Owner of more than 10% of a Class of Security
Buy
2025-11-20
28,867 shares · $261,846
PARMAR KUSH M
Director and Beneficial Owner of more than 10% of a Class of Security
Sell
2025-11-14
200,000 shares · $1,760,000
5AM VENTURES V, L.P.
Beneficial Owner of more than 10% of a Class of Security
Sell
2025-11-14
200,000 shares · $1,760,000
BAKER BROS ADVISORS L.P.
Beneficial Owner of more than 10% of a Class of Security
Buy
2025-11-12
178,044 shares · $1,352,587
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-02-26

TRDA filed an 8-K on February 26, 2026, likely to announce its quarterly or annual financial results.

10-K
10-K
2026-02-26

TRDA filed its 10-K annual report on February 26, 2026, which includes sections on business operations, risk factors, and management's discussion and analysis. Specific financial highlights and risk details were not provided in the available excerpts.

8-K
8-K
2026-01-08
10-Q
10-Q
2025-11-06

TRDA filed its 10-Q on November 6, 2025. While specific financial highlights were not provided in the excerpt, the company identifies 36 risk factors under Item 1A.

8-K
8-K
2025-11-06

TRDA filed an 8-K on November 6, 2025, likely to announce its third-quarter financial results.

10-Q
10-Q
2025-08-06

TRDA filed its 10-Q on August 6, 2025. While specific financial highlights were not provided in the excerpt, the filing identifies 37 risk factors under Item 1A.

8-K
8-K
2025-08-06

TRDA filed an 8-K on August 6, 2025, likely to announce its second-quarter financial results.

8-K
FORM 8-K
2025-06-11
8-K
8-K
2025-06-03
10-Q
10-Q
2025-05-08
8-K
8-K
2025-05-08

TRDA filed an 8-K on May 8, 2025, likely to announce its first-quarter financial results.

8-K
FORM 8-K
2025-04-29
DEF 14A
FORM DEF 14A
2025-04-25
8-K
8-K
2025-03-24
10-K
10-K
2025-02-27
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
STRONG_BUY
5 analysts
Oppenheimer
2026-04-06
Maintains
Outperform Outperform
HC Wainwright & Co.
2026-02-18
reit
Buy Buy
Guggenheim
2026-02-11
init
Buy

Past News Coverage

Recent headlines mentioning TRDA from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile